01251nas a2200361   4500000000100000008004100001260001300042653002600055653001200081653001900093653003100112653002100143653001100164653001200175653002500187653003000212653001300242653002700255653001800282100001600300700001200316700001600328700001400344700001100358700001300369700001500382245006700397856005600464300000900520490000700529520033900536022001400875       2014                            d  c2014 Jan10aAnti-Bacterial Agents10aDapsone10aDNA, Bacterial10aDrug Resistance, Bacterial10aGenes, Bacterial10aHumans10aleprosy10aMycobacterium leprae10apolymerase chain reaction10aRifampin10aSequence Analysis, DNA10aUnited States1 aWilliams DL1 aLewis C1 aSandoval FG1 aRobbins N1 aKeas S1 aGillis T1 aScollard D00aDrug resistance in patients with leprosy in the United States.  uhttps://academic.oup.com/cid/article/58/1/72/372994  a72-30 v583 a<p>Molecular drug susceptibility testing was performed on 39 US patients with leprosy. Of these, 2 had dapsone-resistant Mycobacterium leprae and 1 of these patients also had rifampin-resistant M. leprae. Even though antileprosy drug resistance occurs in this leprosy population, resistance does not appear to be a major problem. </p>  a1537-6591